iSpecimen Inc.

Equities

ISPC

US45032V1089

Software

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.232 USD -7.57% Intraday chart for iSpecimen Inc. -15.64% -53.66%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : ISpecimen Inc., 2023 Earnings Call, Mar 14, 2024
ISpecimen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ISpecimen and TriMetis Life Sciences Announce Strategic Partnership to Help Transform Tissue-Based Research CI
Ispecimen Inc. Announces Executive Changes CI
Transcript : ISpecimen Inc., Q3 2023 Earnings Call, Nov 02, 2023
Earnings Flash (ISPC) ISPECIMEN Posts Q3 Revenue $2.8M MT
ISpecimen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ISpecimen Inc. Provides Revenue Guidance for Third Quarter 2023 CI
ISpecimen Inc. Launches Next-Day Quote Service for Medical Researchers and Biospecimen Providers CI
Ispecimen Expands Provider Network to Enhance Support for Women's Health Research CI
ISpecimen to Reduce Headcount by 20% as Part of Restructuring MT
ISpecimen Enhances Proprietary Marketplace Platform to Streamline Biospecimen Matchmaking for Researchers and Providers CI
Transcript : ISpecimen Inc., Q2 2023 Earnings Call, Aug 02, 2023
Earnings Flash (ISPC) ISPECIMEN Posts Q2 Revenue $1.6M, vs. Street Est of $3.1M MT
ISpecimen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
ISpecimen Inc. Receives A Letter of Resignation from Christopher Ianelli to Resign as A Director CI
ISpecimen Inc. Adds Thirteen New Biospecimen Suppliers to its Proprietary Marketplace Throughout the First Half of 2023 CI
Earnings Flash (ISPC) ISPECIMEN Reports Q1 Revenue $3M, vs. Street Est of $2.6M MT
Transcript : ISpecimen Inc., Q1 2023 Earnings Call, May 04, 2023
ISpecimen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Top Premarket Gainers MT
ISpecimen Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Transcript : ISpecimen Inc., Q4 2022 Earnings Call, Mar 14, 2023
ISpecimen Appoints Eric Langlois as Chief Revenue Officer CI
ISpecimen Appoints Tracy Curley CEO; Launches Search for CFO MT
Chart iSpecimen Inc.
More charts
iSpecimen Inc. is a technology-driven company. The Company's iSpecimen Marketplace platform is designed to transform the biospecimen procurement process to accelerate medical discovery. The Company's technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. Its iSpecimen Marketplace platform has compiled de-identified healthcare data provided by its healthcare supply partners. The platform is built upon a robust healthcare data set comprised of information about available specimens and research subjects. The Company’s platform helps with administrative and reporting functions for researchers, suppliers, and its internal personnel, including user and compliance management. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data, administrative, compliance and reporting.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.251 USD
Average target price
3 USD
Spread / Average Target
+1,095.22%
Consensus
  1. Stock
  2. Equities
  3. Stock iSpecimen Inc. - Nasdaq
  4. News iSpecimen Inc.
  5. ISpecimen Adds Reference Lab in New York for COVID-19 Research Support